SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " GLP-1 " 306 found 🔀 AI-powered Shuffle
Popular weight loss drugs like Wegovy may also target arthritis inflammation
Researchers have discovered that the GLP-1 hormone targeted by drugs like Wegovy is present in very low amounts inside the joints of arthritis patients. That finding suggests high-dose GLP-1 medications could potentially reach the joints and influence inflammation directly, not just help through weight loss. Scientists say this could open the door to a completely new approach to arthritis treatment.
New obesity treatment may help preserve muscle during weight loss
Gwyneth Paltrow and neuroscientist Andrew Huberman explore retatrutide, a new triple-agonist GLP-1 therapy said to reduce side effects and spare muscle.
Dartmouth Health study could point way to sustained weight loss for those who stop using GLP-1 drugs
GLP-1 drugs have transformed obesity treatment, but many patients regain weight after stopping the medication. A new study could point the way to a solution.
Building the Backbone of Metabolic Health: Our Investment in Nourish
Nourish connects patients with registered dietitians for insurance-covered virtual sessions, handling credentialing, insurance verification, and more.
What Is ‘Ozempic Personality’? Patients Say GLP-1 Left Them Emotionally Flat
Some patients taking GLP-1 weight-loss drugs report less pleasure and excitement in life. “It is not in their heads,” doctor says. How to get help if you’re feeling less joy on the medication.
Science Says People Who Lose Weight on GLP-1 Drugs Face More Stigma Than People Who Stay Overweight. That's Just Weird
I have thoughts.
GLP-1 Users Are Taking a Bite Out of the Restaurant Business
Restaurants are pushing protein and smaller portions to keep attracting those eating less.
Greater weight loss from GLP-1 drugs lowers health complication risk
New research to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) shows that, following treatment for obesity or diabetes or both using incretin-based drugs, losing more weight versus less weight, and losing a little weight versus gaining weight, both lead to relatively lower risk of obesity-related conditions.
Can blockbuster GLP-1 weight-loss drugs also protect brain health?
UCSF experts share their research on medications’ potential to slow or reduce risk of dementia and to treat the triggers that drive addiction.
The dark side of weight loss drugs: Ozempic's surprising hidden cost
GLP-1 weight-loss drugs like Ozempic and Wegovy are often celebrated as game-changing solutions—but new research reveals a surprising social twist. People who lose weight using these medications may actually face more judgment than those who lose weight through diet and exercise—or even those who don’t lose weight at all. The stigma seems rooted in a perception that these drugs are an “easy way out,” creating a double bind where individuals are judged both for their weight and for how they choose to manage it.
Weight loss drug Ozempic linked to lower depression and anxiety risk
GLP-1 drugs like semaglutide—best known for treating diabetes and driving weight loss under the brand names Ozempic and Wegovy—may also deliver a surprising mental health boost. In a massive study tracking nearly 100,000 people over more than a decade, researchers found that these medications were linked to significantly fewer psychiatric hospital visits and sick days.
Surgery still outperforms GLP-1 drugs in terms of heart health
Both treatment options are effective, but metabolic and bariatric surgery was linked to more significant cardiovascular risk reductions than GLP-1 medications.
Diet pills, the '90s and why the GLP-1 craze is worrying some experts
Diet pills fueled the thin beauty standard in the 1990s. Are GLP-1 pills sending us back in time? Experts share the differences and concerns.
Multiple GLP-1 drugs linked to lower AFib risk
The popular drugs, originally developed to treat diabetes, were also associated with an improved survival rate. Benefits were seen in patients who did and did not lose significant weight as a result of treatment.
Thanks to GLP-1s, Obesity Experts Are Trying to Understand ‘Food Noise’
Before the rise of GLP-1s, obesity experts didn’t study the internal buzz that compels people to eat. Now that food noise is being switched off, they want to understand it.
What’s the true risk for eating disorders with GLP-1s?
The state of Covid-19 in 2026, a hat to treat depression, and other health news from Morning Rounds
Inside the endoscopic revolution in weight loss
Article explains how bariatric endoscopy — including endoscopic sleeve gastroplasty and transoral outlet reduction — combined with metabolic therapies and GLP-1 receptor agonists is expanding nonsurgical obesity treatment options and reframing obesity as a chronic, multifactorial disease.
Patients taking weight-loss drugs often make 5 critical mistakes, doctor warns
Experts say GLP-1 drugs offer benefits beyond weight loss, but common mistakes like skipped labs and poor nutrition can undermine results or cause harm.
Health insurers raise questions about Medicare program that will offer GLP-1s to seniors for $50
Some health insurers are pushing back against a new program that will allow Medicare beneficiaries to pay $50 per month for GLP-1 medications for weight loss.
Amazon One Medical introduces weight management program with upfront GLP-1 medication costs
The new program combines primary care, pharmacy, and virtual options to treat obesity as a chronic condition—all in one place.
Blockbuster GLP-1 Diabetes and Weight Loss Drugs Fails in Alzheimer’s Trial
Researchers are exploring whether GLP-1 medications used for diabetes and weight loss could treat Alzheimer’s and addiction.
RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves
Hims may have an chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.
Walmart Health Services Expands GLP-1 Access
Walmart’s Better Care Services now offers weight management support for GLP-1 therapies.
Scientists discover natural hormone that reverses obesity
A hormone called FGF21 can reverse obesity in mice by activating a newly identified brain circuit tied to metabolism. Surprisingly, it works in the hindbrain—the same region targeted by GLP-1 drugs like Ozempic and Wegovy—but through a completely different mechanism. Instead of suppressing appetite, FGF21 ramps up the body’s energy burning. This insight could pave the way for more targeted weight-loss and liver disease treatments.
What is ‘Ozempic personality,’ and why does it make life feel ‘meh’?
Doctors and patients across social media are reporting a kind of emotional flattening while on GLP-1 drugs.
This CEO wants to cover weight loss drugs for employees. They're just too expensive.
As demand for GLP-1 drugs surges, employers and insurers are struggling to keep up with the cost. Some are dropping coverage altogether.
Opinion | GLP-1 Experimentation Is Everywhere, and Science Can’t Keep Up
Millions of Americans are experimenting with the drugs. Science can’t keep up.
Opinion | GLP-1 Experimentation Is Everywhere, and Science Can’t Keep Up
Millions of Americans are experimenting with the drugs. Science can’t keep up.
Some people don’t lose weight with GLP-1s. Evidence is building that the drugs are helping anyway
The majority of people who start taking GLP-1 medicines with the hope of losing weight, the drugs can quiet cravings and help them shed stubborn pounds. But research is also continuing to reveal GLP-1 medicines’ benefits independent of weight loss — even if people gain weight.
GLP-1 medicine improves liver health independent of weight loss, study finds
Researchers at Toronto's Sinai Health have found that semaglutide—the active ingredient in popular weight loss drugs that mimic the gut hormone GLP-1—acts directly on a subset of liver cells to improve ...
US states drop Medicaid coverage of GLP-1 weight-loss drugs as demand rises
Experts say any short-term financial benefit will be outweighed by long-term health costs related to obesity
The ‘Wild West’ of peptides is booming. Here’s what’s real, what’s risky and what’s next
In the early 2020s, interest in GLP-1 weight loss drugs exploded. Now, as we move deeper into the decade, a new buzzword is taking over: peptides.
Why Ozempic doesn’t work for everyone: Scientists just found a hidden reason
A new study reveals that popular diabetes and weight-loss drugs like Ozempic and Wegovy may not work as effectively for about 10% of people due to specific genetic variants. These individuals appear to have a puzzling condition called “GLP-1 resistance,” where their bodies produce higher levels of the hormone targeted by these drugs—but don’t respond to it properly.
Health researchers say GLP-1 drug may lower health risks
Penn researchers use AI to surface unreported GLP-1 side effects in Reddit posts
Could mining Reddit with AI help spot drug side effects earlier? A new Penn study suggests it might. Using large language models to map patient posts to standardized medical terms, researchers analyzed more than 400,000 Reddit posts about GLP-1s and found both known side effects and possibly underrecognized symptoms, like menstrual changes. The team says the approach could eventually help generate early safety signals for other drugs and wellness trends discussed online.
Divorce boom may follow use of Ozempic and other GLP-1 drugs, experts warn
Research suggests GLP-1 drugs like Ozempic and Wegovy could double divorce risk, mirroring trends seen in bariatric surgery patients, experts say.
Amazon Pharmacy to Offer Eli Lilly and Company’s New GLP-1 Pill Foundayo via Same-Day Delivery
Amazon Pharmacy (NASDAQ: AMZN), a full-service digital pharmacy that offers fast medication delivery directly to customers' homes, now offers Eli Lilly and C...
If you aren’t losing weight with GLP-1 drugs, this may be one reason why
Two genes involved in gut hormones that influence appetite and digestion may be a factor in how people respond to GLP-1 drugs, according to a new study.
Study suggests GLP-1 drugs have mental health perks
The study doesn’t prove causality or determine why GLP-1s could be a boon to people with mental illnesses.
Top health official predicts ‘price crash’ will bring back GLP-1 coverage
The state's top health official expects GLP-1 weight-loss drug coverage to return as costs fall, reversing current insurance and state agency trends.
Can We Ask Our Son to Go on Weight-Loss Drugs in Exchange for a House?
My husband wants to condition the gift on our son’s getting on a GLP-1 program. I feel that a gift is a gift and you should not extort a grown man.
"Bodies aren't a trend": Body positivity fight endures in the GLP-1 era
"Real people's bodies aren't a trend," one advocate tells Axios.
13 surprising ways GLP-1s may benefit the body, according to science
A condition-by-condition guide to GLP-1 drugs breaks down what’s proven, promising and still untested.
Tom Brady opens up about his health amid GLP-1 surge: Water, movement and discipline
Seven-time Super Bowl champ Tom Brady says he wants to break the stigma around willpower as he joins eMed's mission to bring GLP-1 weight-loss support to workers.
Stopping GLP-1 drugs like Ozempic erodes heart health benefits quickly, new study finds
Stopping GLP-1 drugs like Ozempic quickly erodes heart protection, with two years off the medication raising cardiovascular risk by 22%, a new study finds.
Demand for GLP-1 pills and shots surges, and not just for weight loss
Use of blockbuster anti-obesity drugs like Wegovy and Zepbound is growing, with about 1 in 8 adults in the U.S. saying they currently take the medications.
As demand for GLP-1 pills and shots surges, healthy habits are still key
Whether they’re using weekly shots or daily pills, more Americans than ever are turning to anti-obesity drugs to lose weight and boost health.
Scoop: Weight management company Wondr on the block
Both employer health costs and demand for GLP-1s are rising.
Molecule in python blood could pave way for new obesity drugs, scientists say
Researchers find snake metabolite that suppresses appetite of obese mice ‘without some of side-effects’ of GLP-1 drugs
Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says
Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients with Type 2 diabetes.
Why quitting Ozempic and GLP-1s can be bad for your heart health
People who quit taking popular GLP-1 drugs such as Ozempic might their jeopardize heart health, according to a new study.
Heart benefits fade after stopping GLP-1 medications
One major benefit of taking injected GLP-1 medications is a sizeable reduction in risk for heart attacks, strokes and other heart problems.
An NIH whistleblower warning
The doctors behind the telehealth GLP-1 boom, a men's health office moment, and other health news
Exclusive: Sword Health launches GLP-1 program as it eyes more deals
The company is weighing more M&A and an IPO as early as next year.
Stock Market Today, March 9: Hims & Hers Health Soars on Novo Nordisk Weight-Loss Drug Deal
On March 9, 2026, a new Novo Nordisk pact reshaped this telehealth player’s GLP-1 strategy, margins, and legal risk profile.
Weight Loss Drugs Like Ozempic and Wegovy Show Surprising Heart Health Benefits
A new study suggests that widely used GLP-1 weight-loss drugs may do more than improve metabolic health: they could also protect the heart after a heart attack. Doctors can often reopen the blocked artery that triggers a heart attack, but that is not always the end of the crisis inside the heart
Giving GLP-1 users bite-sized nudges toward healthy habits
Stanford Medicine study shows digital lifestyle nudges may catalyze a critical first step towards behavior change for those taking GLP-1 medications.
Hims & Hers Announces Strategic Shift for US Weight Loss Business
Starting with a new collaboration with Novo Nordisk, the company announced plans to align its US and global strategies with a focus on an increasing variety of FDA-approved GLP-1s Hims Hers Health, Inc. (NYSE: HIMS) today announced a collaboration with Novo Nordisk as part of a new strategy for weight loss care treatments involving GLP-1s, evolving its US offering to match the company’s approach globally. In the US, the company now plans to provide GLP-1 customers with access to a broad assortment of FDA-approved medications and offer compounded semaglutide through the platform on a limited scale. By aligning its domestic and international models in weight loss, Hims Hers will become the largest global consumer health platform for access to more affordable, approved medications. The US weight loss landscape has transformed dramatically since Hims Hers entered the market in 2023. Progress in the industry has made a broader range of FDA-approved GLP-1 treatments
GLP-1 Patients Report New Side Effect—and It’s Worse Than ‘Ozempic Face’
It won’t ruin your face or butt, but it might ruin your life—at least for a little while.
GLP-1 Drugs May Raise the Risk of Osteoporosis and Gout, Study Suggests
New research suggests that prolonged GLP-1 use may increase the risk of certain bone and joint conditions.
GLP-1 Weight-Loss Drugs Prove Effective Across Diverse Patient Groups
By Deanna Neff HealthDay ReporterFRIDAY, March 6, 2026 (HealthDay News) — As the popularity of medications like Ozempic and Trulicity for losing weight continues to soar, folks may wonder: "Will they work for me?" Researchers at Johns Hopkins Bloomberg School of Public Health sought to shed light on ...
Most Patients Keep Weight Off With Fewer GLP-1 Shots, Study Finds
In a recent review, a small group of patients received the injections less frequently but still maintained weight loss and health benefits.
‘Enough’ with blame and shame: The science behind obesity and GLP-1s
In a new book, Yale endocrinologist Ania Jastreboff teams up with Oprah Winfrey to transform how we think about health, weight, and obesity.
Hims expansion may not come in time for risky GLP-1 business
Telehealth company Hims & Hers Health , known for its weight-loss drug business, is promising it can diversify away from its reliance on compounded GLP-1 sales in the U.S., but that may not happen soon enough for investors who are growing impatient.
GLP-1s may increase risk of osteoporosis and gout, new research finds
A large analysis suggests the popular weight loss drugs may carry an increased risk to bone health.
How A $200 Million Pea Protein Business Is Fueling The Ozempic Generation
Since the 1980s, the Lorenzen family has grown its protein powder business, Puris, into an AgTech power player. Now the preferred supplier for food brands seeking craveable recipes for GLP-1 users—it’s helping America become ‘protein independent
Eli Lilly's orforglipron beats Novo Nordisk's GLP-1 pill in tests
Eli Lilly released new data on its oral pill, orforglipron, Thursday, showing it's almost as good as Ozempic. The pill may be available this spring.
In earnings call, Hims CEO addresses scrutiny of GLP-1 compounding
In earnings call, Hims & Hers CEO Andrew Dudum addressed the increased scrutiny on compounded GLP-1s and its impact on the business’s bottom line.
Healthy Returns: FDA chief Marty Makary on compounded GLP-1s, vaccines and China
Makary helms the FDA in the midst of a contentious stretch for the agency, defined by massive staff and budget cuts and sweeping changes to vaccine policy.
General Mills Wants to Win Health-Conscious Shoppers; Cut in Outlook Slams Stock
General Mills is getting aboard the GLP-1 train as the company navigates shaky consumer sentiment. Chief Executive Jeff Harmening told investors Tuesday that the weight-loss drugs will have a lasting influence on the business of food, nudging some consumers toward smaller portions, and more nutrien
Employers find new option for workers' GLP-1 demand
Workers want access to GLP-1s, and employers want to avoid the cost of obesity-related illness.
GLP-1 Envy Was Just the Beginning
A Super Bowl ad by Hims & Hers sells the idea that everyone should want to be billionaire-healthy.
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Eli Lilly is the leader in the GLP-1 space, but here's another GLP-1 stock and a medical device maker to consider.
The Weight-Loss Price Wars Are Breaking Big Pharma’s Business Model
Prices for GLP-1s are falling fast, forcing companies to adapt.
Health Agency Refers Knockoff GLP-1 Provider Hims & Hers to Justice Department
The FDA said it would take “decisive steps” to restrict nonapproved drugs that use GLP-1 active pharmaceutical ingredients.
The Scary Health Risk That Can Sneak Up on GLP-1 Users
Next gen weight-loss medications are powerful — but eating too little can put some patients at serious nutritional risk.
What science says about how weight-loss drugs affect cancer risk
Evidence is mounting that GLP-1 drugs may play a role in reducing cancer risk and deaths from certain cancers.
Why Hims & Hers Health (HIMS) Is Down 6.8% After Amazon Pharmacy Adds Wegovy Weight-Loss Pill
In recent days, Amazon Pharmacy announced it would begin offering Novo Nordisk’s Wegovy once-daily weight-loss pill through both insurance and cash-pay channels, including future availability via its pharmacy kiosks. This move directly targets the fast-growing weight management segment where Hims & Hers Health participates, raising fresh questions about how differentiated and resilient its broader telehealth platform and recurring-care model really are beyond GLP-1 offerings. We’ll now...
Nutrition Strategies to Improve Health With Protein, Fiber, Carbs
Following the release of a new food pyramid and dietary guidelines for Americans, nutrition expert and author of "The Whole Body Reset," Heidi Skolnick joins TODAY with what the recommendations mean for you, how to pace protein intake, how to get more fiber in your diet through foods, what people on GLP-1s should keep in mind about the new guidelines and more.
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference
One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 12-week data from Phase 1 trial of MBX 4291, a dual GLP-1/GIP co-agonist prodrug with potential for once-monthly dosing and improved tolerability for obesity, anticipated in Q4 2026 Nomination of two additional obesity candidates expected in 2026: an amycretin prodrug and a GLP-1/GIP/GCGR triple agonist,
Noom launches a GLP-1-based, long-term, preventive health care program
Noom is expanding the ways it can help people develop long-term health and wellness with the new Proactive Health GLP-1 Program.
The Weight-Loss Drug Revolution—From Shots to Pills and the Science behind It All
Behind the hype of GLP-1 medications lies complex science, serious side effects and a pharmaceutical arms race.
Stopping obesity drugs means people regain weight and lose heart health benefits
Why the weight, and heart risks, return after stopping GLP-1 drugs.
Top Health Trends of 2026: GLP-1 Expansion, AI Wearables, More
Which health trends will be making the biggest waves in 2026? Gretel Schueller, managing editor of health at U.S. News and World Report, joins TODAY to share an exclusive look at their list of the top emerging health trends, including an expansion of GLP-1s for more health conditions, the integration of AI into wearable technology and more.
The science of losing weight : Life Kit: Health
When it comes to weight loss, there are many misconceptions about what works. So if you want to lose weight this year, here's what the science says about the potential health benefits, GLP-1 drugs, exercise and more.Sign up for Life Kit's Guide to Building Strength here: npr.org/strongerFollow us on Instagram: @nprlifekitSign up for our newsletter here.Have an episode idea or feedback you want to share? Email us at lifekit@npr.orgSupport the show and listen to it sponsor-free by signing up for Life Kit+ at plus.npr.org/lifekit
The science of losing weight : Life Kit: Health
When it comes to weight loss, there are many misconceptions about what works. So if you want to lose weight this year, here's what the science says about the potential health benefits, GLP-1 drugs, exercise and more.Sign up for Life Kit's Guide to Building Strength here: npr.org/strongerFollow us on Instagram: @nprlifekitSign up for our newsletter here.Have an episode idea or feedback you want to share? Email us at lifekit@npr.orgSupport the show and listen to it sponsor-free by signing up for Life Kit+ at plus.npr.org/lifekit
The science of losing weight : Life Kit
When it comes to weight loss, there are many misconceptions about what works. So if you want to lose weight this year, here's what the science says about the potential health benefits, GLP-1 drugs, exercise and more.Sign up for Life Kit's Guide to Building Strength here: npr.org/strongerFollow us on Instagram: @nprlifekitSign up for our newsletter here.Have an episode idea or feedback you want to share? Email us at lifekit@npr.orgSupport the show and listen to it sponsor-free by signing up for Life Kit+ at plus.npr.org/lifekit
2026 Health Care Predictions: AI, GLP-1s, MAHA, DEI: Sachin H. Jain, MD, MBA
Sachin H. Jain, MD, MBA, discusses 2026 health care predictions, including AI adoption, GLP-1 demand, MAHA growth, DEI’s return, and policy shifts.
In 2026, Kennedy’s MAHA vision gets put to the test. Here are 3 issues to watch
In 2026, Robert F. Kennedy Jr.'s health policy changes will start playing out on GLP-1s, dietary guidelines, and rural health initiatives.
US health agency to negotiate prices for GLP-1 weight-loss drugs
The U.S. Centers for Medicare and Medicaid Services said on Tuesday it will negotiate drug prices with manufacturers of GLP-1 medications, in an attempt to expand access to the weight-loss treatments.
With FDA approval of Wegovy pill, new era of oral GLP-1 weight loss drugs begins
With FDA approval of Wegovy pill, new era of oral GLP-1 weight loss drugs begins
3 markers of health could help with weight-loss strategies, obesity expert reveals
Obesity medicine specialist Dr. Rocio Salas-Whalen, M.D., author of the new book "Weightless," shared that the best way to determine the suitability of a GLP-1 is through body composition testing.
These people lost their sense of taste. Are GLP-1s to blame?
GLP-1s mute sugar in our bodies. That's impacting our taste buds.
These new 2026 health care laws are taking effect in Pa., N.J. and Del.
Bills on diagnostic breast cancer testing, GLP-1 medications, lead paint and breastfeeding were signed into law.
GLP-1s may weaken the pelvic floor, impacting women's health –– and their sex lives
GLP-1 side effects like constipation and muscle mass loss can lead to uncomfortable pelvic floor symptoms like bladder leakage and painful sex.
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction in total body fat (3.5 lbs; p=0.07), and a 3.2% increase in lean mass (4.0 lbs; p=0.01), with no statistically significant changes in the placebo group Sustained and robust suppression of serum Activin E supports expectations for continued improvements in body composition, further fat loss, and p
Driven by GLP-1s, prescription drug spending explodes at major health insurers
Some insurers have spent more on drugs in nine months this year than they did in all of 2024. Cost of weight loss drugs a major factor, STAT analysis finds.
Here’s What the World Health Organization Had to Say About GLP-1s in its First-Ever Guideline on the Drugs
The health agency supports the long-term use of the medications in combination with a healthy diet and exercise, and calls for equitable access to the drugs